Comparative effects of PP242 and rapamycin on mTOR signalling and NOTCH signalling in leukemia cells

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 809-814

  Ono, Aya ^a   Oike, Ryo ^a   Okuhashi, Yuki ^a   Takahashi, Yusuke ^a   Itoh, Mai ^a   Nara, Nobuo ^a   Tohda, Shuji ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Leukemia; MTOR; NOTCH; Rapamycin

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; P85 S6 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; S6 KINASE; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION; HUMANS; INDOLES; LEUKEMIA; PHOSPHORYLATION; PURINES; RECEPTORS, NOTCH; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84875907050     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, Park S, Lacombe C, Mayeux P and Bouscary D: Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 24: 1686-1699, 2010.
2. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C and Fruman DA: Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16: 205-213, 2010.
3. Okuhashi Y, Nara N and Tohda S: Effects of gamma-secretase inhibitors on the growth of leukemia cells. Anticancer Res 30: 495-498, 2010.
4. Pancewicz J and Nicot C: Current views on the role of NOTCH signaling and the pathogenesis of human leukemia. BMC Cancer 11: 502, 2011.
5. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, Caparros E,Buteau J, Brown K, Perkins SL, Bhagat G, Agarwal AM, Basso G, Castillo M, Nagase S, Cordon-Cardo C, Parsons R, Zuniga-Pflucker JC, Dominguez M and Ferrando AA: Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13: 1203-1210, 2007.
6. Wong GW, Knowles GC, Mak TW, Ferrando AA and Zuniga- Pflucker JC: HES1 opposes a PTEN-dependent check on survival, differentiation, and proliferation of TCRβ-selected mouse thymocytes. Blood 120: 1439-1448, 2012.
7. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F and Berger R: NB4, a maturation-inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77: 1080-1086, 1991.
8. Tohda S, Sakano S, Ohsawa M, Murakami N and Nara N: A novel cell line derived from de novo acute myeloblastic leukaemia with trilineage myelodysplasia which proliferates in response to a NOTCH ligand, Delta-1 protein. Br J Haematol 117: 373-378, 2002.
9. Tohda S, Sato T, Kogoshi H, Fu L, Sakano S and Nara N: Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors. Leuk Res 30: 1385-1390, 2006.
10. Shan X, Czar MJ, Bunnell SC, Liu P, Liu Y, Schwartzberg PL and Wange RL: Deficiency of PTEN in Jurkat T-cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation. Mol Cell Biol 20: 6945-6957, 2000.
11. Ming XF, Burgering BM, Wennstrom S, Claesson-Welsh L, Heldin CH, Bos JL, Kozma SC and Thomas G: Activation of p70/p85 S6 kinase by a pathway independent of p21ras. Nature 371: 426-429, 1994.
12. Laser M, Kasi VS, Hamawaki M, Cooper G 4th, Kerr CM and Kuppuswamy D: Differential activation of p70 and p85 S6 kinase isoforms during cardiac hypertrophy in the adult mammal. J Biol Chem 273: 24610-24619, 1998.
13. Choo AY, Yoon SO, Kim SG, Roux PP and Blenis J: Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-typespecific repression of mRNA translation. Proc Natl Acad Sci USA 105: 17414-17419, 2008.
14. Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E, Chiarini F, Bortul R, Melchionda F, Pagliaro P, Pession A, McCubrey JA and Martelli AM: Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 25: 781-791, 2011.
15. Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M and Konopleva M: Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood 120: 2679-2689, 2012.